<DOC>
	<DOCNO>NCT00121407</DOCNO>
	<brief_summary>The purpose study demonstrate Visudyne therapy patient occult classic subfoveal choroidal neovascularization ( CNV ) lesion , acceptable safety profile , significantly reduce risk vision loss compare placebo ( sham treatment ) .</brief_summary>
	<brief_title>Visudyne® Occult ( VIO )</brief_title>
	<detailed_description>This randomize , placebo-controlled , double mask , multicenter , Phase III study . Patients stratify study center randomize Visudyne therapy placebo 2:1 ratio , respectively . Patients receive either single intravenous dose Visudyne placebo follow 15 minute start infusion light application . Follow-up visit occur every three month ( +/- 2 week ) duration study . Re-treatment may administer every three month ( Month 21 visit ) evidence CNV leakage detect fluorescein angiography ( judged Investigator ) . At baseline follow-up visit , patient undergo follow assessment : ophthalmic examination , best-corrected visual acuity , color fundus photography , fluorescein angiography . Indocyanine green ( ICG ) angiography conduct baseline , Month 12 , Month 24 . Optical coherence tomography ( OCT ) do baseline , Month 3 , Month 6 , Month 12 , Month 24 . Adverse event concomitant medication assess throughout study .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>Patients men woman age 50 year old . Patients must occult CNV secondary AMD study eye , without concurrent retinal disease present may also associate CNV ( e.g. , pathologic myopia , ocular histoplasmosis syndrome , etc. ) . In case eye eligible , one eye treat decision eye treat make patient physician . Patients must blood associated lesion must show progression disease within precede 3 month randomization treatment . For purpose study , disease progression define either : documented loss vision ( six letter ETDRS chart least three line Snellen chart ) use bestcorrected visual acuity assessment ; document fluorescein angiographic evidence 10 % increase lesion ’ great linear dimension . Patients must lesions study eye follow characteristic determine fluorescein angiography : Evidence occult CNV involve geometric center foveal avascular zone ; The lesion occult CNV classic CNV ; The area occult CNV must occupy least 50 % total lesion . Patients must bestcorrected visual acuity score study eye 73 34 letter ( approximate Snellen equivalent 20/40 20/200 ) , inclusive . Visual acuity measure ETDRS chart use procedure develop TAP/VIP study . Patients must meet least one follow criterion : CNV lesion ≤4 MPS disc area ; Visual acuity score &lt; 65 letter . Female patient childbearing potential must pregnant lactating , must negative pregnancy test ( serum urine ) baseline must practice adequate method birth control . Acceptable method birth control include intrauterine device ( IUD ) ; oral , implanted injected contraceptive ; barrier method spermicide . Patients must sign approve informed consent complies relevant regulatory requirement prior undergo studyrelated procedure . Patients great linear dimension ( GLD ) entire lesion exceeds 5400 micron Patients lesion size &gt; 6 MPS disc area ( 15.24 mm2 ) Patients CNV lesion size &gt; 4 MPS disc area associate bestcorrected visual acuity score &gt; =65 letter ( approximate Snellen equivalent 20/50 good ) initial visit . Patients know hypersensitivity/allergy Visudyne , porfimer sodium , porphyrins ; porphyria porphyrin sensitivity ; hypersensitivity sunlight bright artificial light . Patients follow study eye : tear ( rip ) RPE ; vitelliformlike lesion outer retina ( e.g. , pattern dystrophy basal laminar drusen ) ; idiopathic parafoveal telangiectasis , retinal lesion anastomosis , central serous retinopathy . Patients know allergy fluorescein dye . Patients additional ocular disease irreversibly compromise , followup , could likely compromise visual acuity study eye include amblyopia , elevate intraocular pressure ( ≥30 mm Hg ) , anterior ischemic optic neuropathy , clinically significant diabetic macular edema , severe non proliferative diabetic retinopathy , proliferative diabetic retinopathy cataract ( lens capsule ) obscure easy identification CNV lesion biomicroscopy fluorescein angiography . Patients unable photographed document CNV , e.g. , due medium opacity , cataract obscure CNV , allergy fluorescein dye , lack venous access . Patients treatment CNV study eye photodynamic therapy ( PDT ) , transpupillary thermotherapy ( TTT ) , local treatment ( submacular surgery ) . Previous laser photocoagulation therapy acceptable , provided subfoveal . Patients participate clinical study receiving , receive experimental systemic treatment AMD ( e.g. , retinoic acid , thalidomide ) investigational new drug within 12 week prior start study treatment . Patients undergone intraocular surgery within last two month Nd : YAG capsulotomy within last month study eye . Patients history moderate severe hepatic impairment ( patient history may include laboratory test perform result indicate within normal limit ) .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>Age Related Macular Degeneration ( AMD )</keyword>
	<keyword>Photodynamic Therapy ( PDT )</keyword>
	<keyword>Visudyne</keyword>
</DOC>